Novartis Says Phase 3 Ianalumab Study Showed Extended Immune Thrombocytopenia Disease Control

MT Newswires Live12-09

Novartis (NVS) said Tuesday that its phase 3 study evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia showed extended disease control by 45%, based on the primary endpoint of time to treatment failure.

Patients also achieved a "significantly" higher rate of sustained platelet count improvement at six months compared with placebo plus eltrombopag, meeting the key secondary endpoint, Novartis said.

Additionally, ianalumab was well tolerated with no new safety signals, and its side effect profile was consistent with previous studies, Novartis said.

Shares of the company were up over 2% in recent trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment